Profile data is unavailable for this security.
About the company
GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. It has a global network of about 12 vaccines manufacturing sites.
- Revenue in USD (TTM)38.36bn
- Net income in USD4.27bn
- LocationGSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|GSK:LSE since |
|Affinivax Inc||Deal completed||31 May 2022||31 May 2022Deal completed||-35.75%||3.30bn|
|Sierra Oncology Inc||Deal completed||13 Apr 2022||13 Apr 2022Deal completed||-37.76%||2.08bn|